Dihydroorotate Dehydrogenase (DHODH)

Cat. No.

A38266

CAS No.

183946-00-1

hDHODH-IN-2

hDHODH-IN-2 is a selective inhibitor of human dihydroorotate dehydrogenase (hDHODH), functioning as an analogue of Leflunomide's active metabolite. This compound exhibits anti-inflammatory properties, making it relevant for research into autoimmune diseases and other inflammatory conditions. Its mechanism of action targets pyrimidine synthesis, effectively reducing the production of lymphocytes involved in inflammatory responses.

Cat. No.

A38286

CAS No.

1364791-86-5

DHODH-IN-13

DHODH-IN-13 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), displaying an IC50 of 4.3 μM for rat liver DHODH. This hydroxyfurazan analog of A771726 demonstrates significant biological activity in modulating pyrimidine metabolism. DHODH-IN-13 is primarily utilized in research related to rheumatoid arthritis and other autoimmune conditions, making it a valuable tool for exploring therapeutic strategies in these areas.

Cat. No.

A38299

CAS No.

881826-17-1

hDHODH-IN-14

hDHODH-IN-14 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibiting an IC50 value of 0.469 μM. This compound is utilized primarily in research focused on modulating the de novo pyrimidine biosynthesis pathway. Its inhibitory effects make hDHODH-IN-14 a valuable reagent for studying metabolic processes and potential therapeutic strategies in various diseases, including autoimmune disorders and cancer.

Cat. No.

A38375

CAS No.

2742675-85-8

DHODH-IN-19

DHODH-IN-19 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), an essential enzyme located in the inner membrane of human mitochondria that is critical for pyrimidine biosynthesis. This compound demonstrates significant anticancer activity by inhibiting tumor growth, making it a valuable tool for research in cancer and inflammatory diseases. Its mechanism of action offers potential insights into the metabolic pathways involved in these conditions.

Cat. No.

A38421

CAS No.

1644156-41-1

hDHODH-IN-7

hDHODH-IN-7 is a selective inhibitor of human dihydroorotate dehydrogenase (DHODH). It exhibits antiviral activity with a reported pMIC50 of 7.4, indicating its potential efficacy in reducing viral replication. This compound is suitable for research applications involving the study of viral infections and the regulation of pyrimidine biosynthesis.

Cat. No.

A38457

CAS No.

1364791-88-7

DHODH-IN-15

DHODH-IN-15 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor, exhibiting an IC50 of 11 μM in rat liver DHODH assays. This hydroxyfurazan analog of A771726 demonstrates significant biological activity, making it a valuable tool for investigating the role of DHODH in various metabolic pathways. Its application extends to research on rheumatoid arthritis, contributing to the understanding of therapeutic strategies for inflammatory diseases.

Cat. No.

A38487

CAS No.

2619531-95-0

DHODH-IN-25

DHODH-IN-25 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 value of 5.4 nM for human DHODH. This compound demonstrates significant biological activity and is particularly relevant for research applications involving acute myeloid leukemia (AML). DHODH-IN-25 provides valuable insights into the therapeutic potential of targeting pyrimidine biosynthesis in cancer treatment.

Cat. No.

A38496

CAS No.

1148125-93-2

DHODH-IN-4

DHODH-IN-4 is a dihydroorotate dehydrogenase (DHODH) inhibitor targeting both human and Plasmodium falciparum DHODH. With IC50 values of 4 μM for PfDHODH and 0.18 μM for HsDHODH, this compound demonstrates significant potential as an antimalarial agent. It is suitable for research applications focused on understanding malaria pathology and developing effective treatments against Plasmodium infections.

Cat. No.

A38539

CAS No.

418775-30-1

DHODH-IN-24

DHODH-IN-24 is a potent inhibitor of human dihydroorotate dehydrogenase (DHODH) with an IC50 value of 91 nM. This compound effectively impairs the proliferation of rapidly dividing cells by hindering pyrimidine synthesis. DHODH-IN-24 is an important tool for investigating the role of DHODH in various biological processes and may have applications in the research of autoimmune diseases and cancer therapy.

Cat. No.

A38559

CAS No.

2554623-76-4

P1788

P1788 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine synthesis pathway. By inhibiting DHODH, P1788 induces DNA damage and has demonstrated potential in various cancer research applications. Its effects on pyrimidine metabolism make it a valuable tool for studying cellular proliferation and apoptosis.

Cat. No.

A38684

CAS No.

3000567-76-7

RORγ/DHODH-IN-1

RORγ/DHODH-IN-1 is a dual inhibitor targeting RORγ and dihydroorotate dehydrogenase (DHODH) with IC50 values of 9.7 nM and 100 nM, respectively. This compound effectively inhibits the replication of SARS-CoV-2, human cytomegalovirus (HCMV), and adenovirus type 5 (HAdV5), making it a valuable tool in viral research. Its dual mechanism of action allows for potential applications in understanding viral-pathogen interactions and developing therapeutic strategies against viral infections.

Cat. No.

A50662

CAS No.

2299252-72-3

Izumerogant

Synonyms: IMU-935

Izumerogant (IMU-935) is an orally active dual inhibitor of RORγ and DHODH, with IC50 values of 10 nM and 98 nM, respectively. This compound effectively disrupts the replication of various viruses, including SARS-CoV-2, HCMV, and HAdV5, demonstrated by EC50 values ranging from 3.6 to 17 nM. Izumerogant serves as a valuable tool for investigating antiviral mechanisms and therapeutic strategies against viral infections.

Cat. No.

A52313

CAS No.

2426616-55-7

DSM502

DSM502 is a pyrrole-based inhibitor targeting Dihydroorotate Dehydrogenase (DHODH). It demonstrates nanomolar potency against Plasmodium DHODH and effectively inhibits Plasmodium parasites while showing no activity against mammalian DHODHs. This selectivity makes DSM502 a valuable tool for research into malaria and other Plasmodium-related diseases.

Cat. No.

A52405

CAS No.

2989908-08-7

DSM705 hydrochloride

DSM705 hydrochloride is a potent inhibitor of Dihydroorotate Dehydrogenase (DHODH), targeting the enzymatic activity essential for the de novo pyrimidine synthesis in Plasmodium species. It demonstrates high nanomolar potency against P. falciparum and P. vivax DHODH with IC50 values of 95 nM and 52 nM, respectively, while sparing mammalian DHODH enzymes. This compound is valuable for research into antimalarial therapeutics and understanding the biochemical mechanisms of Plasmodium infections.

Cat. No.

A52455

CAS No.

425629-94-3

PfDHODH-IN-2

PfDHODH-IN-2 is a specific inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH), exhibiting potent activity with an IC50 of 1.11 µM. This compound serves as an effective antimalarial agent, making it valuable for research focused on malaria and the development of therapeutic strategies against this disease. Its mechanism of action targets the pyrimidine biosynthesis pathway, providing a crucial approach for disrupting parasite proliferation.

Cat. No.

A52496

CAS No.

2653225-38-6

DSM705

DSM705 is a pyrrole-based inhibitor of Dihydroorotate Dehydrogenase (DHODH). It demonstrates nanomolar potency against Plasmodium DHODH and exhibits significant activity against Plasmodium parasites while sparing mammalian DHODHs. This compound is a potent antimalarial agent, making it a valuable tool for research in malaria treatment and related studies.

Cat. No.

A52552

CAS No.

212375-00-3

DHODH-IN-29

DHODH-IN-29 is a covalent inhibitor targeting Dihydroorotate Dehydrogenase (DHODH) in Leishmania braziliensis, exhibiting an IC50 value of 0.5 μM. This compound demonstrates significant potential for the development of antileishmanial therapies, making it a valuable tool in the study and treatment of leishmaniasis. Its selective inhibition of LbDHODH positions it as a key reagent for exploring therapeutic strategies against this parasitic disease.

Cat. No.

A52625

CAS No.

92872-51-0

PfDHODH-IN-3

PfDHODH-IN-3 is a potent inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 of 47 nM. This compound exhibits strong antimalarial activity, effectively inhibiting the growth of Plasmodium in animal models. PfDHODH-IN-3 is valuable for research focused on antimalarial drug development and understanding the mechanisms of Plasmodium resistance.

Cat. No.

A52980

CAS No.

1281861-06-0

DSM267

DSM267 is a triazolopyrimidine compound that preferentially inhibits Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC50 of 38 nM, demonstrating significant selectivity over human DHODH with an IC50 exceeding 100,000 nM. This reagent is valuable for in vitro systematic screening and characterizing the pathways of resistance evolution in Plasmodium falciparum against DHODH inhibitors. Its use supports research into antimalarial resistance mechanisms and facilitates the development of novel therapeutic strategies.

Cat. No.

A53019

CAS No.

1254834-91-7

Genz-669178

Genz-669178 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), demonstrating an IC50 range of 0.015-0.05 μM against Plasmodium species. It effectively inhibits P. berghei and P. falciparum strains 3D7 and Dd2, with respective IC50 values of 0.068, 0.008, and 0.01 μM. In vivo studies indicate that Genz-669178 exhibits significant anti-malarial efficacy in P. berghei-infected mice, with an ED50 of 13-21 mg/kg/day, alongside favorable pharmacokinetic properties. This compound serves as a valuable tool for malaria research and drug development.

Cat. No.

A53039

CAS No.

898743-92-5

DSM74

DSM74 is a potent inhibitor of dihydroorate dehydrogenase (DHODH) in both Plasmodium falciparum (PfDHODH) and Plasmodium berghei (PbDHODH), with IC50 values of 0.28 μM and 0.38 μM, respectively. This orally active compound exhibits significant antimalarial activity, effectively inhibiting the growth of Plasmodium species in animal models. It is a valuable tool for researchers investigating the mechanisms of malaria and developing novel therapeutic strategies.

Cat. No.

A53043

CAS No.

2011769-21-2

DSM-421

DSM-421 is an orally active inhibitor of dihydroorotate dehydrogenase, an enzyme involved in pyrimidine biosynthesis. This compound exhibits significant antiplasmodium activity, making it a valuable tool for research on malaria and other parasitic diseases. Its mechanism of action presents important applications in developing therapeutic strategies targeting nucleotide synthesis in pathogenic organisms.

Cat. No.

A53112

CAS No.

2057420-00-3

BRD7539

BRD7539 is a potent inhibitor of PfDHODH, exhibiting an IC50 value of 0.033 μM. This compound demonstrates significant efficacy against multidrug-resistant asexual blood-stage Plasmodium falciparum (Dd2 strain) with an EC50 of 0.010 μM, as well as against liver-stage Plasmodium berghei, with an EC50 of 0.015 μM. BRD7539 serves as a valuable tool for research targeting malaria drug development and resistance mechanisms.

Cat. No.

A53528

CAS No.

3000567-45-0

RORγ/DHODH-IN-2

RORγ/DHODH-IN-2 is a potent dual inhibitor of RORγ and DHODH, exhibiting IC50 values of 11.9 nM and 90 nM, respectively. This compound demonstrates significant antiviral activity against multiple viruses, including SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively. RORγ/DHODH-IN-2 is ideal for research applications targeting immune signaling pathways and viral infections.

Cat. No.

A70032

CAS No.

16344-26-6

DHODH-IN-17

DHODH-IN-17 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), with an IC50 value of 0.40 μM. This compound is pivotal for studying the metabolic pathways involved in acute myeloid leukemia (AML) and may aid in the development of targeted therapies for this condition. Its ability to inhibit DHODH highlights its potential use in cancer research, particularly in understanding tumor metabolism and proliferation.